Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus rivoceranib maintenance after camrelizumab-chemotherapy induction in advanced esophageal squamous cell carcinoma
ChiCTR2600116141Phase 2Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by First Hospital of China Medical University. Primary endpoint: Progression-free survival. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600116141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116141.